Clinical Trial Update: Post-Marketing Surveillance Study of OTEZLA

View source ↗

Summary

This document reports the completion of a post-marketing surveillance study evaluating the safety of Otezla (apremilast) in patients with psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• OTEZLA (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Status: COMPLETED